Amanote Research
Register
Sign In
Nilotinib Übertrifft Imatinib in Der First-Line Weiterhin
Info Onkologie
doi 10.1007/bf03362993
Full Text
Open PDF
Abstract
Available in
full text
Date
April 1, 2011
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Nilotinib in Der First-Line Zugelassen
Info Onkologie
Complete Molecular Response Induced by Nilotinib in a Patient Previously Treated With Imatinib, Nilotinib and Dasatinib
Clinical Management Issues
Medicine
Accounting
Management
Business
Response to Imatinib in Villonodular Pigmented Synovitis (PVNS) Resistant to Nilotinib
Clinical Sarcoma Research
Oncology
Evaluation of Nilotinib in Advanced GIST Previously Treated With Imatinib and Sunitinib
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Tierische Insuline /Trotz Rückzügen Auch Weiterhin in Der Schweiz Erhältlich
Schweizerische Ärztezeitung
Nutzen Der First-Line-Therapie Mit Cetuximab Bestätigt
Best Practice Onkologie
Oncology
Pancreatic Enzyme Elevation in Chronic Myeloid Leukemia Patients Treated With Nilotinib After Imatinib Failure
Haematologica
Hematology
Major Molecular Response Induced by Nilotinib as First Line Treatment in a LMC Patient With Intermediate Sokal Risk
Clinical Management Issues
Medicine
Accounting
Management
Business
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
